Lilly announces senior management changes
INDIANAPOLIS — Two senior leaders at Eli Lilly are retiring, the company said Tuesday.
The Indianapolis-based drug maker announced the Dec. 31 retirements of Lilly SVP and Bio-Medicines president Bryce Carmine, and president of manufacturing operations Frank Deane. Carmine and Deane have worked at Lilly for 36 years and 33 years, respectively. Lilly USA president Dave Ricks will replace Carmine, while SVP global drug product manufacturing Maria Crowe will replace Deane.
"We’ll certainly miss Bryce and Frank and the extraordinary leadership they provided," Lilly chairman, president and CEO John Lechleiter said. "At the same time, we’re very fortunate to have talented leaders who are well prepared and ready to step into these critical roles."
Bazi International introduces superfruit energy shot
DENVER — Bazi International on Tuesday launched its energy shot Bazi, which contains a blend of eight superfruits.
According to the company, only 3-out-of-10 consumers have tried energy shots or drinks. Some of the key barriers of entry include health and safety concerns and an underlying belief that the shots are not good for you.
"Being successful in the increasingly crowded beverage and shot categories, products must be differentiated to be successful," stated Bazi CEO Debbie Wildrick. "Bazi is unique in that it provides the body with an enhanced blend of energy and nutrition, [and] is supercharged with antioxidants and powerful nutrients."
ReportersNotebook — Chain Pharmacy, 10/10/11
SUPPLIER NEWS — The Food and Drug Administration has approved Mylan’s promethazine hydrochloride tablets, a generic drug for treating allergies, in the 12.5-mg, 25-mg and 50-mg strengths. Promethazine hydrochloride tablets, which are manufactured by several companies, had sales of about $42 million during the 12-month period ended in June, according to IMS Health.
Sandoz, the generic drugs arm of Swiss drug maker Novartis, announced the FDA approval of Omnitrope (somatropin [rDNA origin]) for children with growth failure due to Turner syndrome. Sandoz said Omnitrope was now approved for all the same indications as the reference product, Pfizer’s Genotropin.
Omnitrope originally received approval from the FDA for pediatric growth-related disorders in 2006 under a new drug application. Though Omnitrope technically is a follow-on biologic, no abbreviated approval pathway for follow-on biologics existed at the time.
The FDA approved a generic skeletal muscle relaxant made by Sagent Pharmaceuticals, Sagent said. The generic drug maker will offer orphenadrine citrate injection in 60 mg/2 mL, single-dose vials. Various versions of the drug had sales of about $4.3 million in 2011, according to IMS Health.
Amgen announced the FDA’s approval of the biotech drug Prolia (denosumab) for increasing bone mass in men and women who are at risk of fractures due to hormone ablation treatments they are receiving for prostate and breast cancer, respectively. “Bone loss and fractures are recognized adverse effects of hormone ablation therapies, but we have not had an approved treatment option to prevent these problems for our patients,” Massachusetts General Hospital Cancer Center genitourinary malignancies program head Matthew Smith said.
A drug made by Boehringer Ingelheim and Eli Lilly showed “meaningful and durable” reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at a conference in Europe. BI and Lilly presented data from their 2,121-patient, 102-week phase-3 study of Tradjenta (linagliptin) at the European Association for the Study of Diabetes’ 47th annual meeting in Lisbon, Portugal, showing that the drug, combined with other drugs, lowered HbA1C levels by 0.8% over the long term.